Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Related to this article
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
2
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
3
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
4
Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC
5